EuropeENPublic drug registration overview
European Union (EU) Pharmaceutical Registration Pathway
Market Overview Market profile: EU pharmaceutical regulation combines EMA, the European Commission, and national competent authorities. A centralised authorisation can cover EU Mem...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: European Union (EU) Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Regulatory maturity: High. ICH/CTD, GMP, pharmacovigilance, paediatric planning, orphan designation, conditional approval, and accelerated assessment are mature.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Market profile: EU pharmaceutical regulation combines EMA, the European Commission, and national competent authorities. A centralised authorisation can cover EU Member States and relevant EEA countries.
- Regulatory maturity: High. ICH/CTD, GMP, pharmacovigilance, paediatric planning, orphan designation, conditional approval, and accelerated assessment are mature.
- Core decision: First decide whether the product must use the centralised procedure or can use mutual recognition, decentralised, or national procedures.
Regulators
- EU scientific evaluation: European Medicines Agency (EMA) evaluates centralised marketing authorisation applications.
- Grant of authorisation: The European Commission grants centralised marketing authorisations.
- Member States: National competent authorities handle national procedures, inspection cooperation, pharmacovigilance, and parts of market access.
Product Types and Review Pathways
| Pathway | Typical scope | Result |
|---|---|---|
| Centralised Procedure | Biotech medicines, advanced therapies, orphan medicines, and defined innovative therapeutic areas | One EU-level marketing authorisation |
| Decentralised Procedure | Products not yet authorised in any Member State and not mandatory centralised | Parallel multi-country review |
| Mutual Recognition Procedure | Product already authorised in one Member State | Other Member States recognise the reference assessment |
| National Procedure | Single-country launch | National marketing authorisation |
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.